Salidroside for Health & Longevity - Quick Reference Sheet

Salidroside for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5 – Audit

Salidroside is the main active compound of golden root, a plant sold as a dietary supplement for fatigue, stress and endurance, and now also made by fermentation. Better endurance and faster recovery from hard training are the best-established effects. Mood steadiness under stress is plausible but unsettled. Lifespan, brain, liver, kidney and cancer claims rest on animals. It is a low-cost, low-risk, short-term experiment. (Full Review)

Protocol

Standard isolated-compound dose
60 mg daily
Bioengineered salidroside; the regimen used in the only randomized trial in healthy adults, commonly continued for 8–12 weeks
Standard extract-based dose
200–600 mg daily
Rhodiola rosea extract standardized to 3% rosavins and 1% salidroside, delivering roughly 2–6 mg salidroside
Best time of day
Morning
Ideally 30–60 minutes before training or demanding cognitive work; afternoon and evening dosing is where restlessness and delayed sleep onset concentrate
Time to effect
Perceived exertion
Within hours
Acute effects after a single dose
Performance & mood markers
2–4 weeks
Measurable changes in trials
Metabolic changes
Longer
Where they occur at all

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Bipolar disorder, current or historical
  • Active hormone-sensitive or actively treated cancer, outside of oncology supervision
  • Severe chronic kidney disease (estimated filtration rate below 30 mL/min/1.73 m², or dialysis)
  • Severe hepatic impairment (Child-Pugh Class C)
  • Children and adolescents under 18
Key Interactions
  • CYP3A4 substrates with a narrow safety margin (tacrolimus, cyclosporine, ivabradine, simvastatin; whole-root extract)
  • P-glycoprotein substrates (digoxin, dabigatran, apixaban; whole-root extract)
  • Antidiabetic medication (metformin, sulfonylureas, insulin, SGLT2 inhibitors)
  • Antidepressants, particularly monoamine oxidase inhibitors (phenelzine, selegiline) and serotonergic agents (sertraline, fluoxetine)
  • Over-the-counter stimulants and decongestants (caffeine, pseudoephedrine, phenylephrine)
  • Supplements with additive glucose-lowering effects (berberine, alpha-lipoic acid, chromium, cinnamon extract)
  • Supplements with additive stimulant or mood effects (ashwagandha, ginseng, tyrosine, high-dose caffeine)
  • Anticoagulant therapy and elective surgery (two-week pre-surgical stop)

Risk & Side Effects

  • High: Mild, self-limiting adverse effects
  • Medium: Drug-interaction risk from whole-root extracts; species substitution and content variability in products
  • Low: Additive glucose lowering; overstimulation and sleep disruption
  • Speculative: Loss or reversal of benefit at high doses; blood-vessel growth signaling and theoretical tumor concern

Monitoring

Marker Target Why
Fasting glucose 70–85 mg/dL Detects additive glucose lowering, the main metabolic risk
Fasting insulin 2–5 µIU/mL Tracks the insulin-sensitivity claim directly
Glycated hemoglobin 4.8–5.4% Confirms that any glucose shift is sustained, not a one-off reading
Alanine and aspartate aminotransferase 10–26 U/L (women), 10–30 U/L (men) Liver safety, and the organ where the fatty-liver claim would show
High-sensitivity C-reactive protein < 0.5 mg/L The inflammation mechanism claimed for the compound
Estimated glomerular filtration rate > 90 mL/min/1.73 m² Clearance route for the compound; falling values raise exposure
Heart-rate variability No established salidroside target; track change from the individual's own 7-day baseline Objective proxy for stress-axis load and recovery
Morning cortisol 10–15 µg/dL The stress-hormone axis the compound is claimed to modulate

Cadence: Baseline before starting; glucose and insulin rechecked at 4 weeks, the full panel at 12 weeks, then every 6–12 months on continued use. Daily fasting-glucose self-checks for the first 2 weeks apply to anyone taking glucose-lowering medication.

Qualitative Assessment

  • Perceived exertion during a standard training session at fixed output
  • Time to fatigue during demanding cognitive work, particularly late in the day
  • Sleep onset latency and subjective sleep quality, which is where harm would appear first
  • Daytime energy stability, especially the mid-afternoon dip
  • Mood steadiness and irritability under a known recurring stressor